Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A.
The clinical characteristics and RET proto-oncogene (RET‑PO) mutation status of a patient with multiple endocrine neoplasia type 2A pedigree (MEN2A) was analyzed with the aim of preliminarily exploring the molecular mechanisms and clinical significance of the disease. Clinical characteristics of a single MEN2A patient were analyzed. Genomic DNA was extracted from the peripheral blood of the proband and 10 family members. The 21 exons of RET‑PO were PCR amplified and the amplified products were sequenced. Of the family members, 5 exhibited a C634Y (TGC→TAC) missense mutation in exon 11 of RET‑PO, among which 2 family members were screened as mutation carriers, while the others did not exhibit clinical symptoms of the mutation. The screening and analysis of RET‑PO mutations for the MEN2A proband and the family members suggests potential clinical phenotypes and enables assessment of the risk of disease development, thus providing useful information for determining the surgical timing of preventive thyroid gland removal.
Department of Surgical Oncology, Taizhou Cancer Hospital, Taizhou Branch of Fudan University, Taizhou, Zhejiang 317502, P.R. China.
Rongbiao
R
Ying
Department of Surgical Oncology, Taizhou Cancer Hospital, Taizhou Branch of Fudan University, Taizhou, Zhejiang 317502, P.R. China.
Jun
J
Feng
D000328:Adult; D015415:Biomarkers; D004252:DNA Mutational Analysis; D005260:Female; D005500:Follow-Up Studies; D005820:Genetic Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000097:blood / Q000175:diagnosis* / Q000235:genetics* / Q000601:surgery; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret